Topics

Medical Research
Amgen ends trial for stomach-cancer drug due to increase in deaths
Amgen ends trial for stomach-cancer drug due to increase in deaths

Biotech giant Amgen Inc. said it stopped clinical trials of an experimental stomach-cancer treatment due to an increase in patient deaths. The Thousand Oaks-based company said Monday that an independent committee found a higher number of deaths among patients using a combination of rilotumumab, the experimental drug, and chemotherapy compared with people receiving chemotherapy only. "While we are disappointed with these results, we will work with lead investigators to further analyze the data in order to help inform future research and therapies in this area," said Sean Harper, Amgen's executive vice president of research and development. Harper said there's "a...

Loading